Efficacy and safety of latanoprost for glaucoma treatment: a three-month multicentric study in India.
OBJECTIVE
To evaluate the short-term efficacy and safety of 0.005% topical latanoprost in Indian eyes.


METHODS
Prospective non-randomised open-label multicentric trial.


METHODS
One hundred and fifty patients with ocular hypertension (OHT), primary open-angle, pseudoexfoliation or pigmentary glaucoma were enrolled at four centers. Each center contributed at least 20 patients. Following baseline measurements, 0.005% latanoprost was applied topically once daily in the evening for three months. Patients were examined at 2, 6 and 12 weeks. The primary outcome measure was mean intraocular pressure (IOP) reduction. The mean diurnal variation of IOP (difference between highest and lowest IOP) at baseline and at 12-weeks was compared.


RESULTS
One hundred and thirty of 150 enrolled patients completed the study. One randomly selected eye of each patient was included for analysis. At three months, latanoprost reduced the mean IOP from 24.9 (+/- 3.16) mmHg at baseline to 16.10 (+/- 2.7) mmHg, a reduction of 35.25%. 83% had a reduction in IOP of > 25%. The IOP reduction was maintained throughout the study period, and was not affected by gender or age of the patient. One eye did not show any response to the drug. Daytime diurnal variation of IOP was reduced from 4.5 to 2.9 mmHg. 20 patients had conjunctival hyperemia. Six patients had side effects requiring withdrawal from the study.


CONCLUSIONS
In this short-term multicentric study, latanoprost effectively reduced IOP and stabilised the diurnal curve in Indian eyes. There were no clinically significant ocular or systemic adverse effects.
Thomas
Ravi
R
L V Prasad Eye Institute, L V Prasad Marg, Banjara Hills, Hyderabad 500-034, India. ravithomas@lvpei.org
Parikh
Rajul
R
Sood
Devendra
D
Vijaya
L
L
Sekhar
G Chandra
GC
Sood
Narendra N
NN
Baskaran
M
M
Prasad
K Kalyani
KK
D000328:Adult; D002940:Circadian Rhythm; D017889:Exfoliation Syndrome / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D005902:Glaucoma, Open-Angle / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D009798:Ocular Hypertension / Q000188:drug therapy / Q000503:physiopathology; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects* / Q000627:therapeutic use*
D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost